$CAVA

CAVA GROUP, INC.

AlphAI earnings readFiscal Second Quarter 2026 · AUG 11CAVA GROUP REPORTS SECOND QUARTER 2026 RESULTSVerdict: strong

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

4
1
3
$482K
Thompson Douglas W.
0%
See all $CAVA insider activity →

Starbucks initiated, Expedia downgraded: Wall Street's top analyst calls

Analysts made several rating changes: Wolfe upgraded Paychex (PAYX) citing stable employment trends. UBS upgraded Union Pacific (UNP) to Buy with a $339 price target, expecting strong 2027 volume growth. Needham upgraded Rocket Pharmaceuticals (RCKT) to Buy with a $9 target after FDA reaffirmed study design. JPMorgan upgraded Credicorp (BAP) to Overweight with a $482 target, seeing strong EPS growth. Morgan Stanley downgraded Expedia (EXPE) to Underweight with a $235 target, citing weaker assets

CAVA sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 8 news stories mentioning CAVA (CAVA GROUP, INC.). Coverage has skewed bullish: 4 bullish, 1 neutral, and 3 bearish.

Recent CAVA coverage spans financial news, earnings and insider activity.

In the last 30 days, CAVA insiders filed 2 SEC Form 4 transactions — 2 purchases ($482K) and no sales. The most active reporter was Thompson Douglas W., Chief Operations Officer, with 1 filing.

What's driving CAVA

AlphAI scores every news story that mentions CAVA with an AI model for sentiment and relevance, and aggregates insider trades from CAVA GROUP, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $CAVA

Score

Starbucks initiated, Expedia downgraded: Wall Street's top analyst calls

Analysts made several rating changes: Wolfe upgraded Paychex (PAYX) citing stable employment trends. UBS upgraded Union Pacific (UNP) to Buy with a $339 price target, expecting strong 2027 volume growth. Needham upgraded Rocket Pharmaceuticals (RCKT) to Buy with a $9 target after FDA reaffirmed study design. JPMorgan upgraded Credicorp (BAP) to Overweight with a $482 target, seeing strong EPS growth. Morgan Stanley downgraded Expedia (EXPE) to Underweight with a $235 target, citing weaker assets

WEN, CMG, SBUX, MCD, CAVA Stocks: Seaport Sees One Stock Stand Out Amid Restaurant Traffic Weakness, Valuation Risks

Seaport Research initiated coverage on five restaurant chains, rating Wendy's (WEN), Chipotle (CMG), Starbucks (SBUX), and McDonald's (MCD) 'Neutral', while naming CAVA Group (CAVA) 'Buy'. The firm cited weaker restaurant traffic, rising oil prices, and inflation as pressures on the industry. CAVA was highlighted for its growth potential and lower brand awareness, with a $58 price target.

$CAVAMed

Learn Why The Bull Case For CAVA Group Stock Could Change Following Earnings Beat

CAVA Group reported Q2 2026 earnings beating expectations, with 17 new restaurants and 9% same-store sales growth. However, higher food, labor, and delivery costs pose challenges. The company maintained its fiscal 2026 outlook and is expanding, including a second St. Louis area location. Analysts note margin pressure as a key risk, with net profit margins at 4.8% compared to 13% last year. The company projects $2.4B revenue and $145.2M earnings by 2029, assuming 20.4% annual revenue growth.

Why Is Cava (CAVA) Down 18.7% Since Last Earnings Report?

Cava Group (CAVA) shares fell 18.7% since its last earnings report, despite beating Q2 estimates with $0.19 EPS and $368.44M revenue, up 18.8% and 31.3% YoY. Growth driven by 17 new restaurants and 9% same-restaurant sales. However, margins contracted due to higher costs, with food and labor expenses rising.

Related tickers